Disruption of p53 in Human Cancer Cells Alters the Responses to Therapeutic Agents

p53 knockout in human colorectal cancer cell line HCT116. Details are described in the paper by Bunz et al., 1999 Description (Set) Proposed Use (Set) The p53 gene is inactivated in the majority of human cancers. JHU scientists determined that p53 knockout cell lines have altered responses to therapeutic agents, being sensitized to DNA damaging agents but resistant to anti-metabolite 5-fluorouracil. This novel knock-out line provides the basis for a new drug screen to identify compounds that specifically kill cells with p53 mutations.

Inventor(s): Vogelstein, Bert

Type of Offer: Licensing



« More Medical Patents

---